Last reviewed · How we verify
NCT00395278
Development of Serologic Assays for Human Herpes Virus-8
trial in Kaposi Sarcoma in 394 participants. Completed in 10 December 2020.
10 December 2020
Quick facts
| Lead sponsor | National Institutes of Health Clinical Center (CC) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 394 |
| Start date | 30 October 2006 |
| Primary completion | 10 December 2020 |
| Estimated completion | 10 December 2020 |
| Sites | 1 location across United States |
Conditions studied
- Kaposi Sarcoma — all drugs for Kaposi Sarcoma →
- HIV Infection — all drugs for HIV Infection →
Sponsor
National Institutes of Health Clinical Center (CC)
Who can join
Adults 18 to 99, any sex, with Kaposi Sarcoma or HIV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00395278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kaposi Sarcoma
Currently open trials in the same condition.
- NCT07308886 — Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and I · Phase 2 · recruiting
- NCT06445166 — Propranolol for the Treatment of Kaposi Sarcoma in Adults · Phase 2 · recruiting
- NCT06751355 — Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial · recruiting
- NCT06375122 — Natural History Study of Kaposi Sarcoma · recruiting
- NCT06004011 — AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) · NA · recruiting
Other National Institutes of Health Clinical Center (CC) trials
Trials by the same sponsor.
- NCT06998134 — Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults · recruiting
- NCT05473429 — Characterization of Nociception Phenotype in Individuals With Intellectual Disability · NA · recruiting
- NCT07295795 — Blood Sampling Pre- and Post-Propofol Administration to Characterize the Blood Proteome Using Different Research Assays · recruiting
- NCT05663320 — A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adu · NA · withdrawn
- NCT06778252 — UrbanHEAT: Health Behaviors, Outcomes, and Disparities in Individually Experienced Temperature Across an Urban Community · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00395278 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institutes of Health Clinical Center (CC)
- Last refreshed: 11 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00395278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing